KD01 for bladder cancer: a safety and early efficacy trial
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific type of bladder cancer: either non-muscle-invasive (high-risk) or muscle-invasive (stage cT2-4aN0-1M0).
- If you have non-muscle-invasive cancer, you must have tried BCG treatment and it either didn't work or your cancer came back within a certain time.
- You must be between 18 and 75 years old and in reasonably good general health (ECOG performance status 0 or 1).
- Your blood counts, liver, kidney, and heart function must be within normal limits.
- You cannot have had prior treatment with adenovirus-based therapies, pelvic radiation in the last 5 years, or certain other cancer treatments recently.
- You must be willing to use effective contraception during the study and for 6 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KD01 for women with advanced gynecologic cancers (like cervical or endometrial cancer) that haven't responded to other treatments. It also has a separate part for younger women who want to preserve their fertility.
This study tests a new sustained-release chemotherapy (NDV-01) given directly into the bladder for people with non-muscle invasive bladder cancer that hasn't responded to BCG therapy or is at intermediate risk. It compares the new drug to standard chemotherapy to see if it can delay or prevent cancer from coming back.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This study tests a new drug called VT-101 for people with a type of bladder cancer that hasn't spread into the muscle wall. The goal is to see if the drug is safe and effective. It might be an option if you have already had a biopsy and are not eligible for or refuse surgery.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new Bladder Cancer (BC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.